[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341251-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341251-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","diagnosis-of-malignant-body-fluids-via-cancer-universal-methylation-in-cell-free-dna","Diagnosis of malignant body fluids via cancer-universal methylation in cell-free DNA","","Differentiating malignant from nonmalignant body fluids remains difficult because conventional cytology shows insufficient sensitivity. This study develops and validates a cfDNA methylation diagnostic assay based on universal cancer–only methylation (UCOM) markers in supernatant cell-free DNA (cfDNA). A combined cell-free cancer-universal methylation (CUE) model was built in a prospective multicancer cohort and further verified across additional malignant fluid types, metastases, and cytologically negative cases, showing markedly elevated sensitivity and specificity. The assay complements cytology for diverse body fluids and tumor types.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/diagnosis-of-malignant-body-fluids-via-cancer-universal-methylation-in-cell-free-dna/341251/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/diagnosis-of-malignant-body-fluids-via-cancer-universal-methylation-in-cell-free-dna/341251.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is diagnosing malignant body fluids clinically challenging?","Question",{"text":63,"@type":64},"Conventional cytological analysis has limited sensitivity, with performance varying across study design, methodology, and cytopathologists, and sensitivity also differs by cancer type.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What diagnostic approach does the study propose?",{"text":68,"@type":64},"The study assays universal cancer–only methylation (UCOM) markers in supernatant cell-free DNA from body fluids and combines markers into a cell-free cancer-universal methylation (CUE) model.",{"name":70,"@type":61,"acceptedAnswer":71},"How was the diagnostic assay validated?",{"text":72,"@type":64},"It was developed and validated in an observational prospective multicancer cohort with multiple cancers, then further verified in additional malignant body fluid types and metastases, including cytologically negative malignant samples.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341251,1790102669,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","CLINIC AL  \nMEDICINE  \nAuthorship note: ZM, SD, YY, and CW are co–first authors.  \nConflict of interest: The authors have declared that no conflict of interest exists.  \nCopyright: © 2024, Mao et al. This isan open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nSubmitted: September 7, 2023  \nAccepted: February 14, 2024  \nPublished: April 8, 2024  \nReference information: JCI Insight. 2024;9(7):e175482 .  \n[https://doi.org/10.1172/jci](https://doi.org/10.1172/jci).  \ninsight.175482 .  \nDiagnosis of malignant body fluids via cancer-universal methylation in cell-free DNA  \nZhanrui Mao,1 Shihua Dong,2 Yu Yan,3 Chengyang Wang,2 Wei Li,1 Lu Wang,3 Chengchen Qian,2 Yuanlin Song,3,4 Lin Tong,3,4 and Wenqiang Yu1  \n1Institutes of Biomedical Sciences, Shanghai Public Health Clinical Center, Cancer Metastasis Institute, and Department of General Surgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. 2Shanghai Epiprobe Biotechnology Co., Ltd, Shanghai, China. 3Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. 4Shanghai Respiratory Research Institute, Shanghai, China.  \nBACKGROUND. Differentiating malignant from nonmalignant body fluids remains a clinical challenge because of the unsatisfying performance of conventional cytology. We aimed to improve the sensitivity and ubiquity of cancer cell detection by assaying universal cancer–only methylation (UCOM) markers in supernatant cell-free DNA (cfDNA) .  \nMETHODS. An observational prospective cohort including 1,321 nonmalignant and malignant body fluids of multiple cancers was used to develop and validate a cfDNA UCOM methylation diagnostic assay. All samples were divided into 2 portions for cytology and supernatant cfDNA methylation analysis.  \nRESULTS. The significant hypermethylation of a potentially novel UCOM marker, TAGMe, together with the formerly reported PCDHGB7, was identified in the cfDNA of malignant body fluid samples. The combined model, cell-free cancer-universal methylation (CUE), was developed and validated ina prospective multicancer cohort with markedly elevated sensitivity and specificity, and was further verified in a set containing additional types of malignant body fluids and metastases. In addition, it remained hypersensitive in detecting cancer cells in cytologically negative malignant samples.  \nCONCLUSION. cfDNA methylation markers are robust in detecting tumor cells and are applicable to diverse body fluids and tumor types, providing a feasible complement to current cytology-based diagnostic analyses.  \nTRIAL REGISTRATION. This study was registered [at Chictr.org.cn](at Chictr.org.cn) (ChiCTR2200060532).  \nFUNDING. National Natural Science Foundation of China (32270645, 31872814, 32000505, 82170088), the National Key R&D Program of Ningxia Hui Autonomous region (2022BEG01003), Shanghai Municipal Key Clinical Specialty (shslczdzk02201), Science and Technology Commission of Shanghai Municipality (20DZ2261200, 20DZ2254400), and Major Special Projects of Basic Research of Shanghai Science and Technology Commission (18JC1411101) .  \nIntroduction  \nMetastases of the pleura, peritoneum, and others occur frequently in patients with malignant cancers, in which the dissemination of tumor materials, including cells, cell-free nucleic acids, etc. , systemically leverage several serous membrane fluids and circulate to distant organs (1, 2) . Thus, detecting tumor cells in specific body fluids could help determine the presence of cancer metastases in corresponding sites (3–5), and enable prompt diagnosis and early treatment to optimize life quality and survival for patients with advanced cancer (6) .  \nHowever, the diagnosis of malignant body fluids (MBFs) remains a substantial challenge, as the current gold standard, cytological analysis, is rather unsatisfying given its lack of sensitivity (4, 7) . For example, cytological analysi","cbCainHCPZVrp0JJ","https://ap.wps.com/l/cbCainHCPZVrp0JJ","pdf",4698709,15,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Trial registration\n# Funding\n# Introduction","[{\"question\":\"Why is diagnosing malignant body fluids clinically challenging?\",\"answer\":\"Conventional cytological analysis has limited sensitivity, with performance varying across study design, methodology, and cytopathologists, and sensitivity also differs by cancer type.\"},{\"question\":\"What diagnostic approach does the study propose?\",\"answer\":\"The study assays universal cancer–only methylation (UCOM) markers in supernatant cell-free DNA from body fluids and combines markers into a cell-free cancer-universal methylation (CUE) model.\"},{\"question\":\"How was the diagnostic assay validated?\",\"answer\":\"It was developed and validated in an observational prospective multicancer cohort with multiple cancers, then further verified in additional malignant body fluid types and metastases, including cytologically negative malignant samples.\"}]","Diagnosis of malignant body fluids via cancer-universal methylation in cell-free DNA | PDF",1790041123,38]